Gemifloxacin (mesylate)

Gemifloxacin mesylate (SB-265805S; LB-20304a) is an orally active broad-spectrum quinolone antibacterial antibiotic. Gemifloxacin mesylate inhibits DNA synthesis by inhibiting DNA gyrase and Topoisomerase IV activities. Gemifloxacin mesylate has potent antibacterial activities against gram-positive bacteria in vitro efficacy study, particularly Streptococci and Staphylococci. Gemifloxacin mesylate has been used in the research of respiratory tract infections^[1][2][3]. IC50 & Target:Antibiotic, Bacterial, DNA synthesis, Topoisomerase IV^[1] In Vitro:Gemifloxacin has higher antibacterial activity than Moxifloxacin (HY-66011A) against Streptococcus pneumoniae with a MIC₉₀ of 0.06 μg/mL^[2].
Gemifloxacin has highly potent antibacterial activity against Penicillin-resistant strains of S. pneumoniae with a MIC₉₀ of 0.03 μg/mL^[2]. In Vivo:Gemifloxacin has favorable pharmacokinetic profile in animals after oral administration^[1].
Pharmacokinetic Parameters of Gemifloxacin in Sprague-Dawley rats and dogs^[1].

Species	Administration	AUC0-24 (μg/mL·h)	Half-life (h)	Cmax (μg/mL)	Tmax (h)	F (%)
Rat	p.o.; 20 mg/kg	8.50	2.33	2.44	0.33	95.3
Dog	p.o.; 4 mg/kg	7.55	5.12	1.34	1.13	71